ORUM (475830) - Net Assets
Based on the latest financial reports, ORUM (475830) has net assets worth ₩119.57 Billion KRW (≈ $81.03 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩312.82 Billion ≈ $211.99 Million USD) and total liabilities (₩193.25 Billion ≈ $130.96 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ORUM strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩119.57 Billion |
| % of Total Assets | 38.22% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ORUM - Net Assets Trend (2022–2025)
This chart illustrates how ORUM's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see 475830 market cap overview.
Annual Net Assets for ORUM (2022–2025)
The table below shows the annual net assets of ORUM from 2022 to 2025. Also explore net asset momentum of ORUM to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩130.89 Billion ≈ $88.70 Million |
+7.49% |
| 2024-12-31 | ₩121.76 Billion ≈ $82.52 Million |
+316.74% |
| 2023-12-31 | ₩-56.18 Billion ≈ $-38.07 Million |
+55.92% |
| 2022-12-31 | ₩-127.46 Billion ≈ $-86.38 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ORUM's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 15050789604000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩18.22 Billion | 13.92% |
| Other Components | ₩112.67 Billion | 86.08% |
| Total Equity | ₩130.89 Billion | 100.00% |
ORUM Competitors by Market Cap
The table below lists competitors of ORUM ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kodiak AI, Inc. Common Stock
NASDAQ:KDK
|
$768.37 Million |
|
Sanofi India Limited
NSE:SANOFI
|
$768.37 Million |
|
Vina Concha To
SN:CONCHATORO
|
$768.61 Million |
|
HomeTrust Bancshares, Inc.
NYSE:HTB
|
$768.68 Million |
|
DoubleU Games Co Ltd
KO:192080
|
$768.27 Million |
|
ADLINK Technology Inc
TW:6166
|
$768.26 Million |
|
Verusa Holding AS
IS:VERUS
|
$768.23 Million |
|
Kyobo Securiti
KO:030610
|
$767.96 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ORUM's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 121,764,729,720 to 130,888,052,360, a change of 9,123,322,640 (7.5%).
- Net loss of 41,969,171,950 reduced equity.
- New share issuances of 49,566,873,770 increased equity.
- Other factors increased equity by 1,525,620,820.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-41.97 Billion | -32.06% |
| Share Issuances | ₩49.57 Billion | +37.87% |
| Other Changes | ₩1.53 Billion | +1.17% |
| Total Change | ₩- | 7.49% |
Book Value vs Market Value Analysis
This analysis compares ORUM's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.66x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | ₩-6090.15 | ₩53400.00 | x |
| 2023-12-31 | ₩-2684.29 | ₩53400.00 | x |
| 2024-12-31 | ₩5817.96 | ₩53400.00 | x |
| 2025-12-31 | ₩6164.55 | ₩53400.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ORUM utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -32.06%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -178105.42%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.29x
- Recent ROE (-32.06%) is below the historical average (-9.19%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.00% | -83402.58% | 0.00x | 0.00x | ₩-50.57 Billion |
| 2023 | 0.00% | 50.38% | 0.84x | 0.00x | ₩73.84 Billion |
| 2024 | -4.71% | -27.46% | 0.14x | 1.26x | ₩-17.92 Billion |
| 2025 | -32.06% | -178105.42% | 0.00x | 1.29x | ₩-55.06 Billion |
Industry Comparison
This section compares ORUM's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $374,207,764,170
- Average return on equity (ROE) among peers: -9.63%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ORUM (475830) | ₩119.57 Billion | 0.00% | 1.62x | $768.37 Million |
| ORIENTBIO Inc. (002630) | $51.96 Billion | -20.94% | 0.39x | $73.37 Million |
| Green Cross (005250) | $1.88 Trillion | -2.88% | 0.99x | $295.07 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $2.94 Million |
| Pharmicell (005690) | $82.82 Billion | -21.94% | 0.22x | $470.89 Million |
| GeneOne Life Science Inc (011000) | $98.51 Billion | -18.93% | 0.39x | $32.81 Million |
| HLB Co. Ltd (028300) | $23.02 Billion | -12.73% | 1.36x | $2.88 Billion |
| Mgenplus Co. Ltd. (032790) | $17.38 Billion | 0.00% | 1.46x | $22.01 Million |
| Daesung Microbiological Labs. Co. Ltd (036480) | $37.00 Billion | 2.34% | 0.69x | $15.81 Million |
| Seoulin Bioscience Co.Ltd (038070) | $48.60 Billion | 8.38% | 0.37x | $24.32 Million |
| Hyundai Bioscience Co. Ltd (048410) | $61.57 Billion | -32.57% | 0.31x | $435.56 Million |
About ORUM
Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases in South Korea and the United States. The company develops ORM-6151, which is in Phase I clinical trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes; ORM-1153, which is in pre-clinical trial for the treatment of acute myeloid … Read more